Welcome to our dedicated page for Reliq Helth Tech news (Ticker: RQHTF), a resource for investors and traders seeking the latest updates and insights on Reliq Helth Tech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Reliq Helth Tech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Reliq Helth Tech's position in the market.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants subject to shareholder approval. The shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.
Reliq Health Technologies has expanded its contract with a large US healthcare group, potentially adding over 30,000 new patients to its iUGO Care platform by the end of 2025. The client, originally using Reliq's services in Florida, will now include facilities in Pennsylvania. This expansion is expected to generate an average revenue of $65 per patient per month. The healthcare group manages over 80,000 patients across Florida, Pennsylvania, Illinois, and Michigan. Reliq's iUGO Care platform offers solutions for remote patient monitoring, chronic care management, and behavioral health integration, which aim to improve health outcomes and reduce care costs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Reliq Helth Tech (RQHTF)?
What is the market cap of Reliq Helth Tech (RQHTF)?
